Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review.

Publication Date

6-2-2023

Presented At:

ASCO

Content Type

Poster

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS